SCHEMBL5546018

SCHEMBL5546018

Cc1cc(C)c(NC2CCN(c3ccc([O])cc3)CC2)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
MAPT P10636 5/20 0.39
LMNA P02545 1/20 0.38
KDM4E B2RXH2 3/20 0.38
GAA P10253 2/20 0.38
MAPK1 P28482 2/20 0.38
ATM Q13315 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
EHMT2 Q96KQ7 3/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
ALDH1A1 P00352 2/20 0.36
GLA P06280 1/20 0.36
KMT2A Q03164 1/20 0.36
MCL1 Q07820 1/20 0.36
USP2 O75604 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PKM P14618 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546024 0.86 ME3 (0.44) TSHRMAPTLMNAKDM4EGAA
SCHEMBL5538936 0.77 MEN1 (0.44) MAPTLMNAKDM4EGAAMAPK1
SCHEMBL5544117 0.76 EHMT2 (0.44) TSHRMAPTKDM4EGAAATM
SCHEMBL5546298 0.75 HPGD (0.43) MAPTLMNAGAARAB9AALDH1A1
SCHEMBL5537144 0.75 MCHR1 (0.42) MAPTKDM4EGAAALDH1A1KMT2A
SCHEMBL5534878 0.73 ME3 (0.47) MAPTMAPK1NPC1RAB9AALDH1A1
SCHEMBL5547883 0.72 HDAC1 (0.44) MAPTLMNAMAPK1ALDH1A1KMT2A
SCHEMBL1848100 0.72 CYP3A4 (0.43) MAPTNPC1RAB9AALDH1A1KMT2A
SCHEMBL5537549 0.71 SMN1; SMN2 (0.42) MAPTLMNAKDM4EGAANPC1
SCHEMBL5542047 0.71 DRD2 (0.45) MAPTLMNAGAAMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TSHR 319/4885MAPT 4117/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.